The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

As breast cancer survivorship improves due to advances in multimodality treatment, the number of patients at risk for local-regional recurrence is rising.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

In this journal activity, participants will review the rationale for de-intensifying treatments for node-negative, hormone-receptor positive breast cancer. This activity will enable participants to be able to discuss de-escalation studies in surgery, systemic therapy and radiotherapy.

This activity provides practitioners with the knowledge to recognize optimal RT management decisions for grade 4 glioma.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

SBRT is an established treatment for adult patients with cancer. This paper provides a summary of the resources available to guide the use of SBRT in children and young adults with cancer. It also identifies opportunities for future work in this area.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

This activity explores the complex role of MYC protein overexpression on cell radiosensitivity and radioresistance in adult and pediatric neuroendocrine malignancies, including small cell lung cancer, large cell neuroendocrine lung cancer, Merkel cell carcinoma, neuroendocrine-differentiated pros

This activity is for Journal Reviewers that completed a review July - September 2025.